Regeneron Presents Results of Evkeeza (evinacumab) in P-III Trial for Homozygous Familial Hypercholesterolemia in Children at EAS 2022
Shots:
- The P-III trial evaluates Evkeeza (15mg/kg, q4w, IV) in children aged 5 to 11yrs. with HoFH for 24wk. treatment period
- The trial met its 1EPs i.e., patients who added Evkeeza to other lipid-lowering therapies showed a 48% reduction in LDL-C in 79% of patients @24wk., absolute 132mg/dL reduction in LDL-C from baseline, reductions in levels of all lipid EPs parameters at first 8wks. of treatment, was generally well-tolerated
- Evkeeza is an investigational mAb targeting ANGPTL & marks the 1st ANGPTL3-targeted therapy that has been approved in the US & EU as an adjunct therapy for patients aged ≥12yrs. with HoFH. The regulatory submission to the US FDA is expected in 2022
Ref: PRNewswire| Image: Regeneron
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
